ParastooBahramiDahiMD

Physician

Overview of Dr. Dahi

Dr. Parastoo Dahi is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Azad University and has been in practice 16 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(631) 593-4107

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 2005 - 2008
Azad UniversityClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2011 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2018 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients Start of enrollment: 2017 Nov 20
Active, not recruiting
Phase 1
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies Start of enrollment: 2018 Mar 29
Completed
Phase 1, Phase 2
Roles: Contact
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 Start of enrollment: 2021 Oct 25
Recruiting
Phase 2
Roles: Contact
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Start of enrollment: 2022 Sep 09
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
Alexander P Boardman, Victoria Gutgarts, Jessica Flynn, Sean M Devlin, Adam Goldman
Haematologica. 2024-11-21
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
Xavier Deschênes-Simard, Martina Pennisi, Miguel-Angel Perales, Gunjan L Shah, Andrew D Zelenetz
Leukemia & Lymphoma. 2024-11-20
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.
Harper Hubbeling, Doris Leithner, Emily A Silverman, Jessica Flynn, Sean Devlin
Clinical Cancer Research. 2024-11-15

Journal Articles

Strategies to Improve Outcomes of Autologous Hematopoietic Cell Transplant in Lymphoma
Parastoo B Dahi, Hillard M Lazarus, Sergio A Giralt, Craig S Sauter, Nature
End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center
Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Th...
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
Parastoo B. Dahi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Fighting Cancer, with the Help of a StrangerOctober 4th, 2018